Comparison of PD-L1 expression before and after neoadjuvant chemoradiation or chemotherapy in stage III non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Koenig, D. [1 ]
Prince, S. Savic [2 ]
Trachsel, B. [3 ]
Hayoz, S. [3 ]
Pless, M. [4 ]
机构：
[1] Univ Hosp Basel, Med Oncol Dept, Basel, Switzerland
[2] Univ Hosp Basel, Inst Pathol & Med Genet, Pathol Dept, Basel, Switzerland
[3] SAKK, Swiss Grp Clin Canc Res, Bern, Switzerland
[4] KSW Kantonsspital Winterthur, Med Oncol & Tumor Ctr, Winterthur, Switzerland
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5P
引用
收藏
页码：S1376 / S1376
页数：1
相关论文
共 50 条
  • [31] Effects of Neoadjuvant Therapy on Programmed Cell Death Ligand 1 (PD-L1) Expression and Immune Microenviroment in Non-Small Cell Lung Cancer (NSCLC)
    Tomaszewski, Kristen
    Huynh, Tiffany
    Kem, Marina
    Mino-Kenudson, Mari
    LABORATORY INVESTIGATION, 2018, 98 : 753 - 754
  • [32] Neoadjuvant treatment with chemotherapy or chemoradiation in stage III non-small cell lung cancer: Analysis of the National Cancer Database.
    Malapati, Sindhu Janarthanam
    Singh, Sunny R. K.
    Kumar, Rohit
    Hadid, Tarik H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] CLINICAL INVESTIGATION Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab
    Sankar, Kamya
    Strohbehn, Garth W.
    Zhao, Lili
    Daniel, Victoria
    Elliott, David
    Ramnath, Nithya
    Green, Michael D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 113 (04): : 752 - 758
  • [34] The influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.
    Nindra, Udit
    Stevens, Samuel Xavier
    Shahnam, Adel
    Pal, Abhijit
    Adam, Tamiem
    Yip, Po Yee
    Lee, Jenny Hj
    Boyer, Michael J.
    Nagrial, Adnan
    Kao, Steven Chuan-Hao
    Bray, Victoria Jane
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18810 - E18810
  • [35] Comparative Effectiveness of Neoadjuvant Chemoradiation Therapy Versus Chemotherapy Alone Followed by Surgery for Patients With Stage III Non-Small Cell Lung Cancer (NSCLC)
    Sher, D. J.
    Fidler, M.
    Liptay, M. J.
    Koshy, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S55 - S55
  • [36] PD-L1 expression in different samples of non-small cell lung cancer
    Kovacevic, M.
    Kern, I.
    VIRCHOWS ARCHIV, 2017, 471 : S104 - S104
  • [37] Comparative Effectiveness of Neoadjuvant Chemoradiation Therapy Versus Chemotherapy Alone Followed by Surgery for Patients With Stage III Non-small Cell Lung Cancer (NSCLC)
    Sher, D. J.
    Fidler, M.
    Liptay, M. J.
    Koshy, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S145 - S146
  • [38] PD-L1 Expression and Molecular Alterations in Non-Small Cell Lung Cancer
    Ebare, K.
    Song, W.
    Opitz, L.
    Rosca, O.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (03): : S52 - S53
  • [39] PD-L1 expression: An emerging biomarker in non-small cell lung cancer
    Adam, Julien
    Planchard, David
    Marabelle, Aurelien
    Soria, Jean-Charles
    Scoazec, Jean-Yves
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2016, 36 (01) : 94 - 102
  • [40] Results of Surgical Treatment After Neoadjuvant Chemotherapy for Stage III Non-Small Cell Lung Cancer
    Carretta, Angelo
    Ciriaco, Paola
    Melloni, Giulio
    Sayed, Imad
    Bandiera, Alessandro
    Ferla, Luca
    Puglisi, Armando
    Zannini, Piero
    WORLD JOURNAL OF SURGERY, 2008, 32 (12) : 2636 - 2642
12345